Menu
Recruiting NCT07716280

Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics

No phase Interventional Lung Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Text Messages (TM+), Chat bot (CA), Video, Reactive Patient Navigation (RPN).
Who it may be relevant to
Registry conditions: Lung Cancer. Basic parameters: 50 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics (LUNG-IS) - PATIENT

Overview

The long-term goal of this program of research is to increase the reach of Lung Cancer Screening (LCS) among low-resource healthcare settings and populations. The proposed project, LUNG-IS, is a mixed-methods, pre-post quasi-experimental design conducted in three Utah safety-net healthcare system clinics. LUNG-IS employs a comprehensive conceptual model with theories, models, and frameworks of implementation and behavioral science, uses rigorous mixed-methods to evaluate factors that influence implementation of LCS, and uses patient navigation to facilitate clinic-community linkages. LUNG-IS leverages existing pathways to care and Centralized Hub infrastructure that enables eligibility assessment, LCS Shared Decision Making (SDM) with clinical decision support, screening referral, and screening logistics assistance to help overcome barriers to LCS completion. The Centralized Hub model uses ubiquitous technologies (i.e., text messaging/telehealth) to enable patients to be assessed for LCS eligibility, engage in SDM if eligible, and be referred for LCS. For patients who decide to complete LCS, they will be provided patient navigation via Community Health Workers designed to address logistical barriers, hesitancy, and financial constraints around completing LCS.

Interventions

  • Behavioral Text Messages (TM+)
    Basic text messages sent directly to the patient's cell phone.
  • Behavioral Chat bot (CA)
    Chat bot to answer frequently asked LCS questions.
  • Behavioral Video
    Educational video about LCS.
  • Behavioral Reactive Patient Navigation (RPN)
    Reactive patient navigation to help get to the LCS appointment.
  • Behavioral Proactive Patient Navigation (PPN)
    Proactive patient navigation to help get to the LCS appointment.

Primary outcome measures

  • Impact of Implementation Strategies on Lung Cancer Screening (LCS) eligibility screening [Time frame: up to 15 weeks after study enrollment]
Secondary outcome measures (2)
  • Impact of Implementation Strategies on LCS Shared Decision Making (SDM) completion [Time frame: up to 7 weeks after completion of LCS eligibility screen]
  • Impact of Implementation Strategies on LCS Completion [Time frame: up to 6 months after placement of LCS referral]

Eligibility criteria

Inclusion criteria

  • Current or former, male and female, smokers.
  • Age 50-80.
  • Primary language English or Spanish.
  • Have a phone that can send/receive text messages.

Exclusion criteria

  • Patients who have never smoked.
  • Patients who are under the age of 50 or above the age of 80.
  • Primary language other than English or Spanish.
  • Do not have access to a phone that can send/receive text messages.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Single group
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 1 center
  • Huntsman Cancer Institute/ University of Utah — Salt Lake City

Identifiers

NCT: NCT07716280 · 187448 · 1U48DP006855-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗